Cubresa has secured a contract with Lawson Health Research Institute of London, Ontario, Canada, to supply the institute with its investigational BrainPET system.
Lawson will use BrainPET in neurological research studies in three areas:
- Developing a way to differentiate between types of dementia using PET and MRI
- Assessing a new method for "quantifying cognitive reserve" among the elderly
- To explore changes in the density of synapses and the role of inflammation in psychiatric disorders, neurodegeneration and cognitive disability following a major cardiac event, the company said.
Cubresa BrainPET is an investigational device and is not available for commercial sale. Image courtesy of Cubresa.BrainPET can be used with 1.5-tesla, 3-tesla, and 7-tesla MRI systems, Cubresa said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
